The Australian Pregnancy Register of Anti-epileptic Drugs: 10 years of progress
Journal of Clinical Neuroscience | ELSEVIER SCI LTD | Published : 2010
The need for collecting a nationwide database for antiepileptic drug (AED) use in pregnancy is described as well as the rationale, methods, funding and logistics of the Australian Pregnancy Register of Anti-epileptic Drugs (APR). Various aspects of treatment with AED have been reported, not only in relation to teratogenicity but also in terms of efficacy of AED, their use in mono and polytherapy, dose-effect relationships and foetal outcomes. The overall effect of the APR in terms of scientific education is also discussed.
Thanks are due to the Scientific Advisory Board and the Ethical Research Committees of St Vincent's Hospital Melbourne, Monash Medical Centre, The Royal Melbourne Hospital and other institutions for their assessments of the study. The APR is indebted for support to the Epilepsy Society of Australia, The Victorian Epilepsy Foundation, Epilepsy Australia and for generous financial support from the pharmaceutical industry, including Sanofi-Aventis, UCB Pharma, Janssen-Cilag, Novartis and Pfizer, and early past support from Glaxo.